Talar Telvizian
Wynnewood, PANPI 1134738859
Payments from drug & device makers
Across 219 payments — averaging $27.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novartis$545
- Eisai Inc.$379
- Johnson & Johnson$348
- Astellas Pharma US Inc$264
- Sanofi$257
- plus $3K from 31 others
What the payments were for
- Speaking & faculty fees$401%
- Food & beverage$5,59094%
- Education$2935%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 52 | $1,453 |
| Novartis | 24 | $545 |
| Eisai Inc. | 16 | $379 |
| Johnson & Johnson(2 entities) | 15 | $348 |
| Astellas Pharma US Inc | 8 | $264 |
| Sanofi | 6 | $257 |
| Seagen Inc. | 3 | $235 |
| Genentech USA, Inc. | 9 | $216 |
| Lilly USA, LLC | 10 | $208 |
| Pfizer | 10 | $205 |
| Tempus AI, Inc | 7 | $196 |
| Boston Scientific | 1 | $164 |
| E.r. Squibb & Sons, L.L.C. | 5 | $151 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $143 |
| Jazz Pharmaceuticals Inc. | 1 | $134 |
| Sobi, Inc | 6 | $126 |
| Bayer | 4 | $81 |
| Daiichi Sankyo Inc. | 3 | $80 |
| Ipsen Biopharmaceuticals, Inc | 3 | $75 |
| Stemline Therapeutics Inc. | 3 | $64 |
| Amgen | 3 | $58 |
| GSK | 2 | $55 |
| Puma Biotechnology, Inc. | 2 | $51 |
| Pharmaessentia USA Corporation | 2 | $47 |
| Incyte Corporation | 2 | $43 |
| AbbVie | 2 | $42 |
| Acrotech Biopharma Inc. | 1 | $40 |
| Deciphera Pharmaceuticals Inc. | 2 | $39 |
| Merck | 2 | $36 |
| Mirati Therapeutics, Inc. | 2 | $35 |
| Caris MPI, Inc. | 1 | $31 |
| Tersera Therapeutics LLC | 1 | $27 |
| Genmab U.S., Inc. | 1 | $24 |
| Apellis Pharmaceuticals, Inc. | 1 | $23 |
| Morphosys, US Inc. | 1 | $19 |
| Novocure Inc. | 1 | $17 |
| Cumberland Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TheraSphere Administration Set$164
- ZEPZELCA$134
- TUKYSA$129
- ULTOMIRIS$128
- IMFINZI$100
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 13 | $236,130 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 13 | $452 |
| Letrozole | 20 | $268 |
| Ibandronate Sodium | 12 | $243 |
| Anastrozole | 11 | $190 |
| Dexamethasone | 17 | $124 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.